NEWS

NEWS

Total 102

92
NeoImmuneTech Appoints Dr. Luke Oh, Ph.D. as New Chief Executive Officer
2024-04-03
91
FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech’s NT-I7 for Advanced Pancreatic Cancer Treatment
2024-01-30
90
Phase II Study Expansion Investigating NeoimmuneTech’s NT-I7 in Head and Neck Cancer
2024-01-29
89
NeoImmuneTech Welcomes a New President for its development and business
2024-01-15
88
QUARTERLY UPDATE (Q4 2023)
2024-01-04
87
NeoImmuneTech and Imugene enter into strategic research collaboration to improve cancer treatments
2023-12-12
86
FDA Grants Orphan Drug Designation to NeoImmuneTech’s NT-I7 for the Treatment of Acute Radiation Syndrome
2023-11-20
85
QUARTERLY UPDATE (Q3 2023)
2023-10-26
84
NeoImmuneTech to Present New Advances on NT-I7 (efineptakin alfa) at 2023 SITC Annual Meeting
2023-10-04
83
NeoImmuneTech Welcomes Two New Members to its Scientific Advisory Board
2023-07-26

1 2 3 4 5 >>>